Antihypotensive Drugs: Roger Joseph Ii Ramos Jecino, RN, M.D

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 28

ANTIHYPOTENSIVE

DRUGS
ROGER JOSEPH II RAMOS JECINO, RN, M.D.
• Sympathetic Adrenergic Agonists or Vasopressor
• Sympathomimmetic drugs are the first choice for treating severe hypotension or shock
• E.g Dobutamine, Dopamine, Ephedrine, Epinephrine, Norepinephrine
• MOA: they react with sympathetic adrenergic receptors to cause the effects of a sympathetic
stress response:
• Increase blood pressure
• Increase blood volume
• Increase strength of cardiac muscle contraction
• Adverse Effects:
• Decrease GI activity
• Nausea and constipation
• Increase respiratory rate
• Changes in blood pressure
• Changes in peripheral blood flow with numbness and tingling
• Alpha specific adrenergic agents
• E.g. Midodrine
• Use to treat orthostatic hypotension
• MOA: activate alpha receptors and produce an increase vascular tone, and
increase in the blood pressure
• Metabolized in the liver and excreted in the urine
• Contraindicated in patient with supine hypertension, CAD, or
pheochromocytoma
ANTIARRHYTHMIC
DRUGS
ROGER JOSEPH II RAMOS JECINO
CLASS I ANTIARRHYTHMIC

• MOA: blocks the SODIUM CHANNELS in the cell membrane during an action
potential, depresses phase O of the action potential
• Subclasses
• Class Ia – disopyramide, procainamide, quinidine
• Class Ib – lidocaine, mexiletine
• Class Ic –flecainide, propafenone
• Indications – tachycardia, potentially life threatening Ventricular Tachycardia
• Metabolism – Liver; Excretion – Kidney
• Able to cross placenta and present in milks
• Adverse events: CNS – dizziness, drowsiness, fatigue, twitching, slurred
speech, etc.; GI – changes in taste, nausea and vomiting; Cardiovascular –
proarrhythmic effects (e.g. Heart block), hypotension, vasodilation and
potential cardiac arrest; Respiratory depression
• Drug to Drug interaction
• Never to combine with beta-blockers and digoxin which are known to cause
arrhythmias
• Quinidne competes for renal transport sites with digoxin. Combining the two lead to
digoxin toxicity
• Drug-Food Reaction
• Quinidine requires a slightly acidic urine for excretion. Avoid food that alkalinize the
urine.
• Grapefruit intereferes with the metabolism of quinidine, leading to increased serum
levels.
CLASS II ANTIARRHYTHMIC
• MOA: beta adrenergic blockers that block beta-receptors, causing a depression of phase 4 of the action potential.
• Heart – decrease heart rate, cardiac excitability and cardiac output, slowing of conduction through AV node.
• Kidney – decrease in the release of renin.
• Pharmacokinetics:
• Oral – acebutolol, propranolol; Intravenous – Esmolol, Propranolol
• Exretion – urine; Metabolism - Liver
• Contraindication
• Sinus bradycardia
• AV blocks
• Hypotension
• Heart Failure
• Asthma/COPD
• Caution: diabetes, thyroid dysfunction
• Adverse Effect
• CNS – dizziness, insomnia, dreams and fatigue
• Cardiovascular – hypotension, bradycardia, AV block
• Respiratory – bronchospasm and dyspnea
• Gastrointestinal – nausea, vomiting, anorexia, constipation
• Drug to Drug interaction
• Verapamil – increases the adverse event, use cautiously
• Insulin – may increase possibility of hypoglycemia, patient should be monitored
closely
• Prototype
• Propranolol – indicated for patient with SVT, Vtach induced by digitalis and
catecholamines
CLASS III ANTIARRHYTHMIC

• Amiodarone, dofetelide, ibutilide and sotalol


• MOA: blocks potassium channels and slow the outward movement of
potassium during phase 3 of the action potential, prolonging it.
• Amiodarone – drug of choice for treating Ventricular fibrillation or pulses
Vtach in cardiac arrest situation
• Pharmacokinetics
• Amiodarone – available on oral and IV forms
• Metabolized in the liver and excreted by the kidney
• Contraindications
• No contraindication when used to life-threatening arrhythmias
• Caution: hypotension, respiratory depression, prolonged QT interval
• Adverse effect
• Liver toxicity – amiodarione
• Ocular abnormality
• Drug to Drug interaction
• Cause serious toxic effects if they are combined with digoxin or quinidine
• Increase risk of proarrhythmia if combined with antihistamines,
phenothiazines, tricyclic antidepressants
CLASS IV ANTIARRHYTHMIC
• MOA: Calcium Channel blockers that blocks the movement of calcium ions across the membrane,
depressing the generation of action potential and delaying phases 1 and 2
• E.g. Diltiazem and Verapamil
• Pharmacokinetics:
• Diltiazem is administered intravenously
• Verapamil is used intravenously when used as an antiarrhythmic
• Metabolized in the liver and excreted in the kidney
• Contraindication:
• Allergy to any calcium channel blocker
• Sick sinus syndrome or heart block
• Pregnancy and lactation
• Heart failure and hypotension
• Adverse events
• Adverse event related to their vasodilation of blood vessels
throughout the body
• CNS: dizziness, weakness, fatigue, depression with beta blockers
• GI upset, nausea and vomiting
• Drug to Drug interaction
• Beta blockers – increases risk of cardiac depression
• Digoxin – additive AV slowing
• Digoxin, carbamazepine, prazosin, and quinidine – increases levels of
toxicity
OTHER ANTIARRHYTHMIC
• Adenosine
• DOC for Supraventircular Tachycardia (SVT)
• It slow the conduction at the AV node, prolongs the refractory period
• Decreases automacity in the AV node.
• Digoxin
• Use to treat atrial arrhythmia
• Slows calcium from leaving the cell prolonging the action potential, slowing
conduction and heart rate
• Positive inotropic effect
NURSING CONSIDERATION
• Assessment
• Assess for contraindications or cautions
• Perform physical assessment
• Assess neurological status
• Assess cardiac status
• Monitor respiratory rate and depth
• Inspect abdomen
• Evaluate skin color, lesions and temperature
• Obtain a baseline ECG
• Nursing Diagnoses
• Decreased cardiac output related to cardiac effects
• Disturbed sensory perception
• Risk for injury related to adverse effect
• Deficient knowledge regarding the drug therapy
• Implementation
• Titrate the dose to the smallest amount needed to achieve control
of arrhythmia
• Monitor cardiac rhythm when initiating or changing the dose
• Ensure emergency life support equipment is readily available
• Administer parenteral forms as ordered
• Consult with the prescriber to reduce the dose in patients with
renal or hepatic dysfunction
• Establish safety precaution
• Arrange for periodic monitoring of cardiac rhythm
• Provide comfort measures
CARDIOTONIC AGENTS
ROGER JOSEPH II RAMOS JECINO
• Cardiotonic Agents – drugs used to increase the contractility of heart muscle
for patient experiencing heart failure
• Heart Failure – heart condition in which the heart fails to pump blood
around the body effectively
• Causes of heart failure
• Coronary Artery Disease – leading cause of heart failure, insufficient supply of blood
to meet the oxygen demands of the myocardium
• Cardiomyopathy – disease of the heart muscle that leads to an enlarge heart and
eventually to complete muscle failure and death
• Hypertensive Heart Disease – eventually leads to an enlarged cardiac muscle
because the heart must work harder than normal to pump against the high pressure
in the arteries
• Valvular Heart Disease – overload of ventricles because the valves do not close
tightly
CARDIOTONIC AGENTS
• Cardiac Glycoside (Digoxin)
• MOA: Increases intracellular calcium and allows more calcium to enter myocardial cells
during depolarization causing the following effects:
• Increased force of myocardial contraction (positive inotropic effect)
• Increased cardiac output and renal perfusion
• Slowed heart rate, owing to slowing of the rate of cellular repolarization (negative
chronotropic effect)
• Decrease conduction velocity through the AV node
• Overall effect is a decrease in the myocardial workload and relief of HF
• Other indications: Atrial flutter, atril fibrillation, paroxysmal atrial tachycardia
• Digoxin has a very narrow margin of safety
• Pharmacokinetics
• Available in oral and IV form
• Excreted in the urine
• Contraindications
• Ventricular tachycardia or fibrillation
• Heart block or sick sinus syndrome
• Idiopathic hypertrophic subaortic stenosis
• Acute MI
• Renal insufficiency
• Electrolyte abnormalities – increased calcium, decreased potassium, decreased
magnesium
• Adverse events
• Headache, weakness, drowsiness and vision changes (yellow halo)
• GI upset and anorexia
• Digitalis toxicity – anorexia, nausea, vomiting, malaise, depression, irregular HR
• Digoxin Immune Fab – antidote for digitalis toxicity
NURSING CONSIDERATION
• Implementation
• Consult with the prescriber about the need for a loading dose when
beginning a therapy
• Monitor apical pulse for 1 full minute before administering the drug, hold
if HR is less than 60 then repeat HR after 1 hr if still low withhold the drug
and inform the prescriber
• Monitor the pulse for any change in quality of rhythm
• Check the dose and preparation carefully
• Administer IV doses slowly for 5 minutes
• Maintain emergency drugs/equipment on standby
• Obtain digoxin level as ordered
• Phosphodiesterase Inhibitors
• E.g. Inamrinone and milrinone
• MOA: blocks the phosphodiesterase enzyme which increases cAMP which increases cellular
calcium levels in the cell
• Indications: short term treat of HF that has not responded to digoxin of diuretic alone
• Pharmacokinetics: available only on IV form, metabolized in the liver and excreted in the urine
• Adverse events: ventricular arrhythmias, hypotension and chest pain
• Drug to drug interaction:
• Furosemide – causes precipitation of inamrinone
• Contraindications
• Severe aortic and pulmonary valvular disease
• Acute MI
• Fluid volume deficit
• Ventricular arrhythmias
• Caution: elderly

You might also like